Levetiracetam Tablet, Film Coated
Product Images NDC 72789-152

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 72789-152). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789152 Label (72789152)

Levetiracetam USP 500 mg film-coated tablets label from PD-Rx Pharmaceuticals, Inc. The label indicates a package of 60 tablets with NDC 72789-152-60. It includes dosage and storage warnings, LOT L20E93, expiration date 03/2022, and instructions for taking the medication. The label features the PD-Rx Pharmaceuticals logo and a barcode as well.*

FDA Label Image

Levefig1 (Levefig1)

A bar chart comparing the percentage of patients responding to treatments with placebo and Levetiracetam 1000 mg/day at two different doses. The vertical axis shows the percentage of patients, and three bars represent Placebo, Levetiracetam 1000 mg/day (N=300) with a response of 37.1%, and Levetiracetam 3000 mg/day (N=101) with a response of 39.6%.*

FDA Label Image

Levefig2 (Levefig2)

A bar chart comparing the percentage of patients across three groups: Placebo (N=111) at 6.3%, Levetiracetam 1000 mg/day (N=106) at 20.8%, and Levetiracetam 2000 mg/day (N=105) at 35.2%. The vertical axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Levefig3 (Levefig3)

A bar chart comparing the percentage of patients between a Placebo group (N=104) and a Levetiracetam 3000 mg/day group (N=180). The chart shows approximately 14.4% of patients in the Placebo group and 39.4% in the Levetiracetam group, depicting an outcome measure distribution.*

FDA Label Image

Levefig4 (Levefig4)

A bar chart comparing the percentage of patients between Placebo (87 patients) and Levetiracetam (101 patients). The chart shows a higher percentage for Levetiracetam at 44.6%, compared to 19.6% for Placebo.*

FDA Label Image

Levefig5 (Levefig5)

A bar chart comparing the occurrence of a condition or outcome between two groups: one receiving placebo and the other receiving Levetiracetam, showing percentages of 45.2% and 72.2% respectively with sample sizes indicated.*

FDA Label Image

Levefig6 (Levefig6)

A bar chart comparing two groups: Placebo (N=64) and Levetiracetam (N=79). The y-axis represents the percentage with a numerical scale up to 100%. The Placebo group shows 45.2%, while the Levetiracetam group shows 72.2%, indicating a higher measured percentage for Levetiracetam.*

FDA Label Image

Levestructure (Levestructure)

Chemical structure of levetiracetam, showing the molecular arrangement with carbon, nitrogen, oxygen, and hydrogen atoms as part of the ring and side groups, consistent with the active ingredient levetiracetam.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.